Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome.
BACKGROUND
Tumor stage mycosis fungoides (MF) is a subtype of cutaneous T-cell lymphoma (CTCL). Tumor stage MF is rarely curable. Treatment is aimed towards controlling the disease and minimizing side effects from therapy.


OBJECTIVE
To characterize clinicopathologic features of tumor stage MF and the impact of clinical characteristics and treatment modalities on patient outcome.


METHODS
A retrospective chart review was conducted on 39 patients with tumor stage MF followed at Vanderbilt University between July 1995 and July 2010.


RESULTS
The median age of diagnosis was 61 years (IQR: 54-70). Sixty-nine percent of the patients were male (27/39). The median follow-up time was 13.6 months (IQR: 5.5-35.9). Among the patients younger than 60 years at the time of initial diagnosis (n = 19), median overall survival (OS) was 7.0 years (95% CI: 2.1-17.9), compared with 3.3 years (95% CI: 2.4-9.3) in patients who were 60 years or older at initial diagnosis. Ten patients with T1/T2 stage at diagnosis had median OS of 5.0 years (95% CI 3.2-7.0). Twenty-eight patients with T3 stage at diagnosis had median OS of 5.8 years (95% CI 2.4-14.2). Median OS for patients with large cell transformation (LCT) and without LCT was 3.3 and 7.7 years, respectively.


CONCLUSIONS
This is a retrospective study with the bias of a tertiary-care referral center.


CONCLUSIONS
Although LCT and older age at diagnosis were not statistically significant negative prognostic indicators of OS, there was a trend towards statistical significance for LCT. Clinical stage at diagnosis may not affect OS in patients who develop tumor stage MF.
Samit A
SA
Patrawala
Karen C
KC
Broussard
Li
L
Wang
Vanderbilt Division of Dermatology. john.zic@vanderbilt.edu.
John A
JA
Zic
D000367:Age Factors; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077610:Bexarotene; D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D005260:Female; D011564:Furocoumarins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods; D012189:Retrospective Studies; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D062606:Tertiary Care Centers; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use; D014467:Ultraviolet Therapy / Q000379:methods
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D011564:Furocoumarins; D013764:Tetrahydronaphthalenes; C515719:psoralen A; D000077610:Bexarotene